Results 191 to 200 of about 210,777 (318)

Breaking the degeneracy in stellar spectral classification from single wide-band images [PDF]

open access: hybrid
Ezequiel Centofanti   +5 more
openalex   +2 more sources

CD44v, S1PR1, HER3, MET and cancer‐associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb

open access: yesFEBS Open Bio, EarlyView.
Novel mAbs could detect cancer‐associated membrane proteins on various type of pancreatic ductal adenocarcinomas (PDAC) by flow cytometry with viable PDAC cells and by immunohistochemistry with PDAC tissues. Results of protein expression were substantiated by mRNA expression by The Cancer Genome Atlas.
Takashi Nakano   +16 more
wiley   +1 more source

A binary system in the S cluster close to the supermassive black hole Sagittarius A. [PDF]

open access: yesNat Commun
Peißker F   +6 more
europepmc   +1 more source

HDAC4 regulates apoptosis in Acan‐CreERT2;HDAC4d/d mice with osteoarthritis by downregulating ATF4

open access: yesFEBS Open Bio, EarlyView.
Using the AcanCreERT2;HDAC4fl/fl genetic mouse model, we further investigated the role of histone deacetylase 4 (HDAC4) in chondrocyte apoptosis. We found that knocking down HDAC4 may be associated with chondrocyte apoptosis by upregulating the activating transcription factor 4 (ATF4)/CAAT/enhancer binding protein homologous (CHOP) signaling pathway ...
Jingrui Huang   +11 more
wiley   +1 more source

Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation

open access: yesFEBS Open Bio, EarlyView.
Osimertinib reduces angiogenesis and PDL1 expression in in ovo tumors, transforming them into ‘cold tumors’ with lower immune activity. Anatomopathological and transcriptomic analyses highlight its therapeutic impact on tumor biology. This study underscores osimertinib's potential to reshape the tumor microenvironment and provides insights into its ...
David Barthélémy   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy